Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2019		Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 21,734,152		$ 103,695
Prepaid expenses and other current assets	1,098,843		156,628
Total current assets	22,832,995		260,323
Property and equipment, net	368,987		29,508
Intangible assets, net	1,223,000		41,692
Right-to-use assets	1,233,894		0
Other assets	145,470		12,800
Total assets	25,804,346		344,323
Current liabilities:
Accounts payable	1,853,306		1,412,951
Accrued expenses	638,186		601,889
Restructuring reserve	1,283,875	[1]	0
Operating lease liabilities- short term	492,086		0
Total current liabilities	4,267,453		2,014,840
Noncurrent liability:
Deferred tax liability	157,000		0
Operating lease liabilities- long term	774,278		0
Convertible promissory notes payable	0		30,000
STOCKHOLDERS' EQUITY
Preferred stock, 5,000,000 shares authorized at June 30, 2019 and December 31, 2018, 0 outstanding	0		0
Common stock, $0.00033 par value, 75,000,000 shares authorized at June 30, 2019 and December 31, 2018, 5,177,487 shares and 3,417,187 shares issued and outstanding at June30, 2019 and December 31, 2018, respectively	1,709		1,128
Additional paid-in capital	38,686,233		19,311,529
Accumulated deficit	(18,082,327)		(21,013,174)
Total stockholders' equity	20,605,615		(1,700,517)
Total liabilities and stockholders' equity	$ 25,804,346		$ 344,323

[1] Restructuring reserve relates to the severance costs incurred by Edge Therapeutics prior to the merger transaction and assumed by the Company as part of the purchase accounting, but not yet paid. The severance costs continue through September 2020. For the six months ended June 30, 2019, the Company paid $786,396 of restructuring expense which was previously recorded on Edge Therapeutics financials.